Drug intelligence / Profile preview

ethanol + nicotine

Development stage
Preclinical
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral, Inhalation
01

Overview

Ethanol + nicotine refers to the concurrent use or co-administration of two psychoactive substances—ethanol (commonly known as alcohol) and nicotine. Both are among the most widely used drugs globally, often co-used in both acute (bingeing/chipping) and chronic patterns. The combination is notable for its unique neurobehavioral effects that differ from either substance alone. Preclinical studies show that combined exposure can produce age-dependent changes in brain function and behavior, such as increased locomotion and reduced anxiety in adolescent animals but not adults[1]. In humans, ethanol potentiates some of the rewarding effects of nicotine—including smoking satisfaction, stimulant/calming sensations, and craving relief—suggesting a synergistic interaction on neural reward pathways[2][6]. The combination can also alter impulsive choice behaviors more than either drug alone[5], with evidence for both synergistic (augmented reinforcement/anxiolysis at low doses) and antagonistic interactions depending on dose ratios[6][5]. Mechanistically, both drugs act on overlapping neural circuits involving dopaminergic signaling; ethanol may enhance or modulate nicotinic acetylcholine receptor activity while also affecting GABAergic/glutamatergic transmission. This dual action likely underlies their high rates of co-use/dependence observed clinically.

Other names
ethanol and nicotinealcohol and nicotineEtOH + NIC
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)NMDAR (Glutamate receptor ionotropic, NMDA)GABRR (GABA-A receptor subunit rho)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on ethanol + nicotine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethanol + nicotine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call